DCTH Insider Trading

Insider Ownership Percentage: 17.94%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Delcath Systems Insider Trading History Chart

This chart shows the insider buying and selling history at Delcath Systems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$600k-$400k-$200k$0$200k$400k$600kTotal Insider BuyingTotal Insider Selling

Delcath Systems Share Price & Price History

Current Price: $12.00
Price Change: Price Decrease of -0.98 (-7.55%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for DCTH up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$12.00Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for Delcath Systems (NASDAQ:DCTH)

61.12% of Delcath Systems stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at DCTH by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$45Mbought$7.29MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More on Delcath Systems

Today's Range

Now: $12.00
Low: $11.57
High: $13.39

50 Day Range

MA: $14.38
Low: $11.80
High: $16.45

52 Week Range

Now: $12.00
Low: $4.26
High: $16.97

Volume

434,586 shs

Average Volume

343,233 shs

Market Capitalization

$400.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

Who are the company insiders with the largest holdings of Delcath Systems?

Delcath Systems' top insider shareholders include:
  1. Gil Aharon (Director)
  2. Rosalind Advisors, Inc (Director)
  3. Gerard J Michel (CEO)
  4. Vojo Vukovic (Insider)
  5. John Purpura (COO)
  6. Sandra Pennell (SVP)
  7. John Richard Sylvester (Director)
Learn More about top insider investors at Delcath Systems.